Trubion Pharmaceuticals Inc. signed its largest deal to date and set a high bar for 2006 by partnering with Wyeth Pharmaceuticals in a potential $840 million agreement to develop Trubion's small modular immunopharmaceutical (SMIP) platform. (BioWorld Today)
